The US Food and Drug Administration (FDA) has approved Merck’s Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia, with cholesterol-lowering medication simvastatin.

The approval is based upon clinical bioequivalence studies in healthy subjects, which demonstrated that the administration of Juvisync is equivalent to the co-administration of corresponding doses of the two individual medications as separate tablets.

Juvisync will enable healthcare providers to help patients who need the blood sugar-lowering benefits of a dipeptidyl peptidase-4 inhibitor and the cholesterol-lowering benefits of simvastatin with the convenience of a single tablet once daily.

However, the therapy should be discontinued immediately if markedly elevated creatine phosphokinase levels occur or myopathy is diagnosed or suspected, the company said.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now